[7-30] pH transistor nanomedicine for cancer surgery and immunotherapy

报告题目: pH transistor nanomedicine for cancer surgery and immunotherapy

报告人:Jinming Gao, Ph.D.

                Professor of Oncology and Pharmacology

                Co-Leader, Cell Stress and Nanomedicine Program

                SimmonsComprehensiveCancerCenter

                UT Southwestern MedicalCenter      

时间:2017年7月30日(周日)下午2:00

地点:苏州大学药学院(二期云轩楼三楼1323会议室)

 

个人简介:

无标题.jpgJinming Gao博士,Simmons Comprehensive Cancer Center,UT Southwestern Medical Center,教授。北京大学本科,美国哈弗大学获博士学位 (导师George M. Whitesides教授),Massachusetts Institute of Technology做博士后研究 (导师Robert S. Langer教授)。主要研究方向为Novel nanomaterials and nanoarchitectures for cancer diagnosis and targeted therapeutic applications。已在Science, Nat Nanotech, Nat Mater, Nat Biomed Eng, Nat Communications, JACS, Angew Chem等杂志上发表了120余篇学术论文,很多工作被选作焦点文章,封面文章,或被媒体报道。所发表论文当前被SCI 期刊引用超过18,000次,H-index为56。获得Distinguished Lecture of Ohio State University, Elkin Lecture of Emory University, Distinguished Scientist Award from the Society of Experimental Biology and Medicine, SEBM best paper award in for 2010 in the Alan MacDiarmid Interdisciplinary Research Category等荣誉。


研究简介:

Cooperativity manifests itself from biology to society (Matthew effect). Biology uses the language of non-covalent self-assembly in addition to covalent bonds to communicate to each other and the outside environment. In many systems, the result of weak but polyvalent interactions often leads to new emergent properties where the whole is bigger than the sum of the parts. We are using the ‘cues’ learned from nature to create cooperative sensors and therapeutics to amplify or digitize biological signals to improve disease diagnosis and therapy. Such examples include the invention of transistor-like pH threshold nanosensors to achieve binary detect ion of tumor margins (tumor = 1, normal tissue = 0) for image-guided cancer surgery, spatio-temporal orchestration of antigen delivery and innate stimulation for cancer immunotherapy, and high throughput screening of drug candidates to improve metabolic disorder and aging. We are closely working with physicians and biotech companies to translate new technologies to the clinics to advance patient care.